/PRNewswire/ Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing.
/PRNewswire/ Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing.
/PRNewswire/ Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing.
/PRNewswire/ Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing.
Soligenix, Inc. (SNGX) announced on Monday that its SGX945 or Dusquetide development program for oral lesions of Behçet's Disease has received a 'Fast Track' designation from the FDA.